Exelixis gains US OK for Cometriq in metastatic medullary thyroid cancer

As expected, the US FDA gave its OK for Exelixis to market its tyrosine kinase inhibitor Cometriq (cabozantinib) as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC) – a decision that came after the US markets closed on 29 November.